company ATRC - SteadyBase

steadybase-$ company ATRC

account_id none on file

legal_name AtriCure, Inc.

ticker ATRC

cik 1323885

domain atricure.com

linkedin_company_url https://www.linkedin.com/company/atricure

entry_point_account_id none on file

name AtriCure Inc.

exchange Nasdaq

sector Health Care

hq Mason, OH, United States

irhttps://ir.atricure.com/

sector index/company/sector/health-care/

calls 19 filings 40 executives 9 family 0

why_nownone on file

calls

SG&A expenses increased 18.9%, primarily from personnel and travel costs due to the measured expansion of our teams globally, as well as one-time consulting costs associated with our planned facilities expansion.

Oct 29, 2024 / receipt, needs a key / Angie Weirich, CFO | earnings call 2024-10-29 | transcript 4cd4dbc7-46f6-4cde-82f9-3583b2f65f22 | chars 12037-12249 | segment 11

Travel is one that comes to mind, just a little bit favorable in the fourth quarter.

Feb 21, 2023 / receipt, needs a key / Angie, CFO | earnings call 2023-02-21 | transcript 0cbe2a30-50b6-4884-9948-1de1cbd20a8d | chars 33342-33426 | segment 34

I do think that we exited the year feeling a bit more relief in some areas, such as travel, where I think early in the year, I think that the pricing that we were seeing, the cost just overall relative to our team's travel was getting a little bit out of hand.

Feb 21, 2023 / receipt, needs a key / Angie, CFO | earnings call 2023-02-21 | transcript 0cbe2a30-50b6-4884-9948-1de1cbd20a8d | chars 52661-52921 | segment 53

A significant driver of this change is the expansion of our team and increasing travel costs, additional physician training programs, a resumption of in-person meetings and trade shows, as well as the investment in our product development pipeline and related regulatory costs.

Aug 2, 2022 / receipt, needs a key / Mike Carroll, CEO | earnings call 2022-08-02 | transcript 6e1e370e-640c-4a84-808a-5253ce05fdee | chars 14716-14993 | segment 14

The change results mainly from the addition of headcount over the last year, expanded physician training programs, including our mobile labs, meetings and trade shows shifting from virtual back to in-person events, and travel returning to normal levels.

May 3, 2022 / receipt, needs a key / Angie, CFO | earnings call 2022-05-03 | transcript d05d085d-4f59-4ac2-9886-9253eb12da5d | chars 14053-14306 | segment 14

Additionally, with the expansion of training programs following the Converge PMA approval in April 2021 and easing travel and meeting restrictions, we experienced an increase in associated costs.

Feb 15, 2022 / receipt, needs a key / Angie Wyrick, CFO | earnings call 2022-02-15 | transcript 1b74351a-48bc-428c-ab44-9f040e203aa2 | chars 14435-14630 | segment 14

The increase resulted mainly from personnel costs, driven by the addition of headcount over last year and variable compensation programs reflecting top-line growth, travel spend returning to normal, and expanding training and market activities as we launch our hybrid AF therapy and continue to drive awareness across our platforms.

Nov 3, 2021 / receipt, needs a key / Angie Wyrick, CFO | earnings call 2021-11-03 | transcript 7001293d-9395-464a-a74d-b15116b653c9 | chars 10710-11042 | segment 11

Yeah, so we've got multiple angles for training. So the first piece is the didactic training. We've had, I think, up to five different didactic trainings. They're typically like a Friday, Saturday type training. They basically come to a city get that training, and then they go through. They've got several EPs and surgeons basically giving the course, lots of dialogue and discussion, generates interest and a much greater knowledge of it. We usually end those courses with a wet lab or some sort of lab afterwards. In addition to that, we have a mobile lab. We've got two mobile labs moving to three that travel across the country. Those are basically busy every week. They're doing anywhere. Each one of them are doing two labs a week, And those labs, basically, they go into the hospital parking lot or to a local parking lot nearby. The surgeons and EPs come into that. We basically do some of the didactic in a shortened version, and then they get their hands on the product and are able to use it. And those are, basically, we're already fully booked through the beginning part of next year, and we're continuing to train people on a regular basis there. And so that's gone extremely well. We do use those labs mostly today for hybrid, but we're going to be adding, within the Encompass launch, And as we add more sites next year, we'll start to add quite a bit from that standpoint as well. So those are kind of two of the main thrusts around some of the training that we're doing. We will do

Nov 3, 2021 / receipt, needs a key / Mike Carroll, CEO | earnings call 2021-11-03 | transcript 7001293d-9395-464a-a74d-b15116b653c9 | chars 23766-25266 | segment 24

The change results mainly from personnel costs, driven by increasing headcount and variable compensation programs, travel spend returning to normal, and expanding training activities as we launch our hybrid AF therapy and continue awareness across our platforms with a combination of mobile cadaver labs and training courses.

Aug 4, 2021 / receipt, needs a key / Angie Weirich, CFO | earnings call 2021-08-04 | transcript 191ca54f-d13f-441e-892c-125261bdf224 | chars 13668-13993 | segment 13

The change results mainly from increased variable cash and stock-based compensation offset partially by lower clinical trial expenses reduce travel and discretionary spend for trade shows and internal meetings.

Apr 27, 2021 / receipt, needs a key / Angie Wyrick, CFO | earnings call 2021-04-27 | transcript 21bf168a-5c2f-47b5-80e5-78d5e8c6d555 | chars 11162-11372 | segment 11

The decline results mainly from reduced variable compensation and travel costs, along with discretionary spend for trade shows and physician training, offset slightly by an increase in stock-based compensation.

Feb 23, 2021 / receipt, needs a key / Angie, CFO | earnings call 2021-02-23 | transcript 01313b4e-08f7-476f-b47e-80a89d77c23e | chars 14043-14253 | segment 14

We do believe most of the areas where we experienced cost savings were impacted by the pandemic and expect spend to be restored to historical levels as our top line improves and travel, training, and event activities increase.

Feb 23, 2021 / receipt, needs a key / Angie, CFO | earnings call 2021-02-23 | transcript 01313b4e-08f7-476f-b47e-80a89d77c23e | chars 14254-14480 | segment 14

filings

Engineering Services Co-op | {"ats": "greenhouse", "city": "Mason", "state": "OH", "job_id": "4404783009", "remote": false, "category": "other", "function": "other", "location": "Mason, OH", "job_titl

company_statement / Sep 14, 2026 / receipt

Engineering Co-op | {"ats": "greenhouse", "city": "Minnetonka", "state": "MN", "job_id": "4404794009", "remote": false, "category": "other", "function": "other", "location": "Minnetonka, MN", "job_tit

company_statement / Sep 14, 2026 / receipt

Finance Co-op | {"ats": "greenhouse", "city": "Mason", "state": "OH", "job_id": "4404800009", "remote": false, "category": "finance_ops", "function": "other", "location": "Mason, OH", "job_title": "Fi

company_statement / Sep 14, 2026 / receipt

Accounting Co-op | {"ats": "greenhouse", "city": "Mason", "state": "OH", "job_id": "4406145009", "remote": false, "category": "finance_ops", "function": "finance", "location": "Mason, OH", "job_title"

company_statement / Sep 14, 2026 / receipt

Sales Training Associate | {"ats": "greenhouse", "city": null, "state": null, "job_id": "4400938009", "remote": false, "category": "sales_expansion", "function": "sales", "location": "United States of

company_statement / Sep 10, 2026 / receipt

Senior Clinical Research Associate | {"ats": "greenhouse", "city": "Mason, OH; Minnetonka", "state": "MN", "job_id": "4398253009", "remote": false, "category": "other", "function": "clinical", "locati